Currently, T-DXd is under investigation in over 40 active phase I–III clinical trials registered on ClinicalTrials.gov and comprising different solid organ malignancies, including HER2+ gastric cancer, non-small cell lung cancer, and urothelial or colorectal carcinoma. The gene discussed is ERBB2; the disease is gastric cancer.